Korean J Obstet Gynecol.  2005 Apr;48(4):844-856.

Current Treatment of Postmenopausal Osteoporosis

Affiliations
  • 1Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea. kimjg@plaza.snu.ac.kr

Abstract

Osteoporosis is a silent disease which causes a serious morbidity such as fracture. Once osteoporosis risk has been established in postmenopausal women, dietary and lifestyle changes, such as exercise, discontinuing tobacco and alcohol use, are helpful in the prevention of osteoporosis. Fall prevention, calcium and vitamin D supplementation remain the foundation. When pharmacologic intervention is warranted, bisphosphonates and selective estrogen receptor modulator have shown the benefit in preventing bone loss and lowering fracture rates. Short term use of estrogen can be considered for the prevention and treatment of osteoporosis in the postmenopausal women with vasomotor symptoms. Calcitonin and parathyroid hormone are also options for the treatment of osteoporosis. Several new agents are in late-stage development and may offer another treatment alternatives.

Keyword

Postmenopausal osteoporosis; Lifestyle change; Pharmacologic therapy

MeSH Terms

Calcitonin
Calcium
Diphosphonates
Estrogens
Female
Humans
Life Style
Osteoporosis
Osteoporosis, Postmenopausal*
Parathyroid Hormone
Selective Estrogen Receptor Modulators
Tobacco
Vitamin D
Calcitonin
Calcium
Diphosphonates
Estrogens
Parathyroid Hormone
Selective Estrogen Receptor Modulators
Vitamin D
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr